Clinical TrialsSanofi and Teva Report Durable Duvakitug Efficacy at 44 Weeks in UC/CD: REL... Sanofi and Teva Report Durable Duvakitug Efficacy at 44 Weeks in UC/CD: REL... Read Post »
Clinical TrialsUltragenyx Reports Long-Term Success of UX111 Gene Therapy for Sanfilippo S... Ultragenyx Reports Long-Term Success of UX111 Gene Therapy for Sanfilippo S... Read Post »
Clinical TrialsRoche’s Gazyva/Gazyvaro Hits pMN Remission in Phase III MAJESTY Trial Roche’s Gazyva/Gazyvaro Hits pMN Remission in Phase III MAJESTY Trial Read Post »
Clinical TrialsSanofi’s NIRSE-GAL Study Shows Beyfortus Protect Infants Beyond First RSV... Sanofi’s NIRSE-GAL Study Shows Beyfortus Protect Infants Beyond First RSV... Read Post »
Clinical TrialsNovartis Vanrafia® Slows IgAN Kidney Decline Novartis Vanrafia® Slows IgAN Kidney Decline Read Post »
Clinical TrialsAstraZeneca Breztri Boosts FEV1 in Asthma Trials AstraZeneca Breztri Boosts FEV1 in Asthma Trials Read Post »
Clinical TrialsLundbeck Reports Positive Phase IIb Results for Bocunebart in Migraine Lundbeck Reports Positive Phase IIb Results for Bocunebart in Migraine Read Post »
Clinical TrialsINmune Bio Advances XPro1595 to FDA-Aligned AD Trial INmune Bio Advances XPro1595 to FDA-Aligned AD Trial Read Post »
Clinical TrialsBridgeBio’s Infigratinib Achieves Breakthrough Phase 3 Results in Ach... BridgeBio’s Infigratinib Achieves Breakthrough Phase 3 Results in Ach... Read Post »
Clinical TrialsINSIGHTT Trial Approved: Sarepta’s HD Therapy Advances INSIGHTT Trial Approved: Sarepta’s HD Therapy Advances Read Post »
Clinical TrialsFDA Clears ArkBio’s AK3280 IND for Phase 2 IPF Trial FDA Clears ArkBio’s AK3280 IND for Phase 2 IPF Trial Read Post »
Clinical Trials Drugs Safety AlertChugai’s NXT007 Shows Promising Safety During Emicizumab Transition in Ha... Chugai’s NXT007 Shows Promising Safety During Emicizumab Transition in Ha... Read Post »
Clinical TrialsGSK’s Arexvy RSV Vaccine Accepted for Review in China GSK’s Arexvy RSV Vaccine Accepted for Review in China Read Post »
Clinical TrialsAstraZeneca Advances Oral GLP-1 Elecoglipron Toward Phase III AstraZeneca Advances Oral GLP-1 Elecoglipron Toward Phase III Read Post »
Clinical TrialsKyowa Kirin Takes Full Global Control of Rocatinlimab After Amgen Exit Kyowa Kirin Takes Full Global Control of Rocatinlimab After Amgen Exit Read Post »
Clinical TrialsTakeda Announces FDA Acceptance of Oveporexton NDA for NT1 Takeda Announces FDA Acceptance of Oveporexton NDA for NT1 Read Post »
Clinical TrialsRoche’s Fenebrutinib Meets Phase III Endpoint in PPMS Roche’s Fenebrutinib Meets Phase III Endpoint in PPMS Read Post »
Clinical TrialsJohnson & Johnson Reports Results from OMNY-AF Study in A-Fib Johnson & Johnson Reports Results from OMNY-AF Study in A-Fib Read Post »
Clinical TrialsFDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label FDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label Read Post »
Clinical TrialsDenali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Denali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Read Post »
Clinical TrialsPfizer’s HYMPAVZI Secures FDA Priority Review for Kids Pfizer’s HYMPAVZI Secures FDA Priority Review for Kids Read Post »
Clinical TrialsFDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... FDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... Read Post »
Clinical TrialsBayer’s Asundexian Cuts Stroke Risk 26% in Phase III Bayer’s Asundexian Cuts Stroke Risk 26% in Phase III Read Post »
Clinical TrialsUCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... UCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... Read Post »
Clinical TrialsFDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease FDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease Read Post »
Clinical TrialsAstellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Astellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Read Post »
Clinical TrialsImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma ImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma Read Post »
Clinical TrialsNovo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Novo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Read Post »
Clinical TrialsPfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Pfizer Bets Big on Monthly GLP-1 After Metsera Deal, VESPER-3 Hits Key Endp... Read Post »
Clinical TrialsJohnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Johnson & Johnson Unveils Real-World Data: ERLEADA Cuts Death Risk by 5... Read Post »
Clinical TrialsPositive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Positive Topline Results: Venglustat Succeeds in Sanofi’s LEAP2MONO GD3 S... Read Post »
Clinical TrialsLundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Lundbeck INFUSE Study: Vyepti Shines for Hard-to-Treat Migraine Read Post »
Clinical TrialsUltragenyx Resubmits BLA for UX111 Gene Therapy in Sanfilippo Syndrome Type... Ultragenyx Resubmits BLA for UX111 Gene Therapy in Sanfilippo Syndrome Type... Read Post »
Clinical TrialsTanabe Pharma’s ZYNLONTA® Hits Key Endpoint in Japanese r/r DLBCL Tr... Tanabe Pharma’s ZYNLONTA® Hits Key Endpoint in Japanese r/r DLBCL Tr... Read Post »
Clinical TrialsFDA Grants Class II Review for Unicycive’s Resubmission of OLC in Hyperph... FDA Grants Class II Review for Unicycive’s Resubmission of OLC in Hyperph... Read Post »
Clinical TrialsChugai Files Tecentriq for MRD-Positive Bladder Cancer in Japan Chugai Files Tecentriq for MRD-Positive Bladder Cancer in Japan Read Post »
Clinical TrialsBiogen’s Litifilimab Wins FDA Breakthrough Therapy Designation for Cutane... Biogen’s Litifilimab Wins FDA Breakthrough Therapy Designation for Cutane... Read Post »
Clinical TrialsFDA Grants Priority Review to Otsuka’s Centanafadine NDA for ADHD Across ... FDA Grants Priority Review to Otsuka’s Centanafadine NDA for ADHD Across ... Read Post »
Clinical TrialsELEVIDYS Delivers 3-Year Sustained Motor Benefits in Ambulatory Duchenne Pa... ELEVIDYS Delivers 3-Year Sustained Motor Benefits in Ambulatory Duchenne Pa... Read Post »
Clinical TrialsNeurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dy... Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dy... Read Post »
Clinical TrialsRoche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase II... Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase II... Read Post »
Clinical TrialsFDA Accepts Eisai-Biogen’s LEQEMBI IQLIK sBLA Under Priority Review FDA Accepts Eisai-Biogen’s LEQEMBI IQLIK sBLA Under Priority Review Read Post »
Clinical TrialsBausch Health’s RED-C Program Comes Up Short in Phase 3 Bausch Health’s RED-C Program Comes Up Short in Phase 3 Read Post »
Clinical TrialsAbbott Shares Five-Year Data Showing Neuromodulation Therapy Cuts Pain-Rela... Abbott Shares Five-Year Data Showing Neuromodulation Therapy Cuts Pain-Rela... Read Post »
Clinical TrialsSanofi’s Amlitelimab Strengthens Phase 3 Evidence in Atopic Dermatitis wi... Sanofi’s Amlitelimab Strengthens Phase 3 Evidence in Atopic Dermatitis wi... Read Post »
Clinical TrialsCorcept Reports Overall Survival Benefit with Relacorilant in Platinum-Resi... Corcept Reports Overall Survival Benefit with Relacorilant in Platinum-Resi... Read Post »
Clinical TrialsBayer and BlueRock’s OpCT-001 Receives FDA Orphan Drug Designation for Re... Bayer and BlueRock’s OpCT-001 Receives FDA Orphan Drug Designation for Re... Read Post »
Clinical TrialsImmunityBio Advances ANKTIVA Toward FDA Resubmission in Papillary NMIBC ImmunityBio Advances ANKTIVA Toward FDA Resubmission in Papillary NMIBC Read Post »
Clinical TrialsFDA Grants Fast Track Designation to BioNTech’s BNT113 for HPV16-Positive... FDA Grants Fast Track Designation to BioNTech’s BNT113 for HPV16-Positive... Read Post »
Clinical TrialsFDA Grants Breakthrough Therapy Designation to Lilly’s Sofetabart Mipitec... FDA Grants Breakthrough Therapy Designation to Lilly’s Sofetabart Mipitec... Read Post »
